Short answer
Bicara Therapeutics Inc. (BCAX) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$36M
- +22.8% YoY · −32.6% QoQ
- EPS (diluted)
- −$0.66
- +94.1% YoY · −32.0% QoQ
Source: XBRL data from the Bicara Therapeutics Inc. (BCAX) Q3 2025 10-Q on SEC EDGAR. USD.
Bicara Therapeutics Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no products approved for sale
- Net loss $36.3M vs $17.5M YoY; operating margin not applicable with no revenue
- R&D expense $33.0M vs $15.9M, led by clinical operations and development at $14.0M
- Cash, equivalents and investments $407.6M at September 30, 2025; aggregate net proceeds $688.3M
- Funding runway into first half of 2029; expects substantial expense increases and future capital needs
Risk Factors
- New financing risk triggered by October 2025 registration statement authorizing up to $400.0 million in securities
- Liquidity risk: $407.6 million cash, equivalents and investments projected to fund operations into first half of 2029
- Clinical regulatory risk: FDA, Health Canada, or EMA may require additional trials or impose clinical holds
- Competitive risk: Keytruda and other HNSCC therapies could reach patients before ficerafusp alfa
- Financial concentration risk: uninsured cash deposits at major financial institutions could become inaccessible
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Bicara Therapeutics Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.